Abstract #4145
MR Guided CED of a Novel Therapeutic for Parkinsons Disease: The Importance of Imaging Feedback
Alastair J Martin 1 , Krystof Bankiewicz 2 , John Bringas 2 , Chad Christine 3 , Marin Thompson 2 , Janine Beyer 2 , and Paul Larson 2
1
Radiology and Biomedical Imaging, UCSF, San
Francisco, CA, United States,
2
Neurological
Surgery, UCSF, San Francisco, CA, United States,
3
Neurology,
UCSF, San Francisco, CA, United States
MR guidance is used to monitor convection enhanced
delivery of a novel gene therapy agent (AAV2-hAADC) in
patients with Parkinsons disease. The therapeutic is
infused bilaterally into the putamen and targeting is
performed with intra-operative MR guidance. Two
infusions are performed in each putamen in order to
maximize coverage of the anatomic structure. Continuous
infusion monitoring with MR imaging revealed sub-optimal
distributions such as reflux along the cannula tract and
shunting along vascular channels. Detection of these
effects permitted adjustments to infusion strategy,
including changing cannula depth and aborting
ineffective infusions.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
